Journals / Tüberküloz ve Toraks / 2009 / Cilt: 57 - Sayı: 1

Malign plevral mezotelyomalı hastaların takip ve tedavisinde plörodezis

Pleurodesis in follow-up and treatment of malignant pleural mesothelioma patients

Pages
22–31
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In feasible patients, a successful pleurodesis with talc increases the survival of patients with MPM, and it can be safely administered.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:We analyzed the necessity of pleurodesis in the follow-up of the patients with malignant pleural mesothelioma (MPM), and how much it contributes to the survival period by determining the indications, efficiency, and reliability of the pleurodesis application. 191 patients were assessed retrospectively and 69 (36%) of them were established with a pleurodesis indication.
📊
Key Findings & Data:In 42 patients accepting pleurodesis, the pleurodesis success was evaluated.
💡
Conclusion & Impact:In feasible patients, a successful pleurodesis with talc increases the survival of patients with MPM, and it can be safely administered.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

We analyzed the necessity of pleurodesis in the follow-up of the patients with malignant pleural mesothelioma (MPM), and how much it contributes to the survival period by determining the indications, efficiency, and reliability of the pleurodesis application. 191 patients were assessed retrospectively and 69 (36%) of them were established with a pleurodesis indication. In 42 patients accepting pleurodesis, the pleurodesis success was evaluated. Factors affecting the success of pleurodesis and the effect of pleurodesis on survival were assessed. Pleurodesis was a success in 26 (62%) of the 42 patients. In the group in which the pleurodesis process was a success, it was observed that KPS and pleural fluid pH were higher (p= 0.030, p= 0.032, respectively). In case of KPS ≥ 80, the sensitivity was: 76.9%, specificity: 50.0%, PPV: 71.4%, and NPV was established as 57.1%. In case of pleural fluid pH > 7.27, the sensitivity was: 92.9%, specificity: 50.0%, PPV: 76.5%, and NPV was observed as 80.0%. In the group in which pleurodesis was a success, the median survival was longer (Log-rank: 11.2; p= 0.0008). Independently from chemotherapy, the chance of living longer for patients whose pleurodesis was a success was 2.6 times higher. A severe complication concerning the process was not observed. Pleurodesis is performed less frequently than it is assumed on patients with MPM. In patients with KPS ≥ 80, pleural fluid pH > 7.27, and with indication, pleurodesis must be administered. In feasible patients, a successful pleurodesis with talc increases the survival of patients with MPM, and it can be safely administered.

Özet

Bu çalışmada plörodezis uygulamasının endikasyonları, etkinliği ve güvenilirliğini belirleyerek, malign plevral mezotelyomalı hastaların takibinde ne kadar gerekli olduğunu ve yaşam süresine katkısı olup olmadığını tartışmayı amaçladık. Yüz doksan bir hasta retrospektif olarak değerlendirildi ve bunların 69 (%36)’una plörodezis endikasyonu konuldu. Plörodezisi kabul eden 42 hastada plörodezis başarısı değerlendirildi. Plörodezis başarısını etkileyen faktörler ve plörodezisin sağkalıma olan etkisi belirlendi. Plörodezis 42 hastanın 26 (%62)’sında başarılıydı. Plörodezisin başarılı olduğu grupta Kornofsky permons skoru (KPS) ve plevral sıvı pH’sı daha yüksekti (sırasıyla; p= 0.030, p= 0.032). KPS ≥ 80 olan hastalarda duyarlılık %76.9, özgüllük %50.0, pozitif prediktif değer %71.4 ve negatif prediktif değer %57.1 olarak belirlendi. Plevral sıvı pH > 7.27 olan hastalarda duyarlılık %92.9, özgüllük %50.0, pozitif prediktif değer %76.5 ve negatif prediktif değer %80.0 olarak belirlendi. Plörodezisin başarılı olduğu grupta median sağkalım daha uzundu (Log-rank: 11.2; p= 0.0008). Kemoterapiden bağımsız olarak, plörodezisi başarılı olan hastaların diğerlerine göre daha uzun yaşama şansları 2.6 kat daha fazlaydı. İşlem sırasında şiddetli bir komplikasyon gözlenmedi. Malign plevral mezotelyomalı hastalarda plörodezis düşünüldüğünden daha az sıklıkta uygulanmaktadır. KPS ≥ 80, plevral sıvı pH > 7.27 olan ve endikasyon doğan hastalarda plörodezis yapılmalıdır. Uygun hastalarda talk ile başarılı plörodezis malign plevral mezotelyomalı hastaların sağkalımını artırır ve güvenle uygulanabilir.

🔖

Cite This Article

YILDIRIM, H., DÜNDAR, E., METİNTAŞ, M., ERGİNEL, S., ALATAŞ, F., AK, G., METİNTAŞ, S. (2022). Malign plevral mezotelyomalı hastaların takip ve tedavisinde plörodezis. Tüberküloz ve Toraks, Cilt: 57 - Sayı: 1, 22–31. https://ajindex.com/articles/618922

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Lee YC, Baumann MH, Maskell N, et al. Pleurodesis practice for malignant pleural effusions in five English-speaking countries: Survey of pulmonologists. Chest 2003; 124: 2229-38
  2. Janssen JP, Collier G, Astoul P, et al. Safety of pleurodesis with talc poudrage in malignant pleural effusion: A prospective cohort study. Lancet 2007; 369: 1535-9
  3. Kolschmann S, Ballin A, Gillissen A. Clinical efficacy and safety of thoracoscopic talc pleurodesis in malignant pleural effusions. Chest 2005; 128: 1431-5
  4. Paschoalini Mda S, Vargas FS, Marchi E, et al. Prospective randomized trial of silver nitrate vs talc slurry in pleurodesis for symptomatic malignant pleural effusions. Chest 2005; 128: 684-9
  5. Viallat JR, Rey F, Astoul P, Boutin C. Thoracoscopic talc poudrage pleurodesis for malignant effusions. A review of 360 cases. Chest 1996; 110: 1387-93
  6. Diacon AH, Wyser C, Bolliger CT, et al. Prospective randomized comparison of thoracoscopic talc poudrage under local anesthesia versus bleomycin instillation for pleurodesis in malignant pleural effusions. Am J Respir Crit Care Med 2000; 162: 1445-9
  7. Dresler CM, Olak J, Herndon JE 2nd, et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest 2005; 127: 909-15
  8. Astoul P. Malignant mesothelioma. In: Light RW, Lee YC (eds). Textbook of pleural diseases. London: Arnold Press, 2003: 435-44
  9. American Thoracic Society. Management of malignant pleural effusions. Am J Respir Crit Care Med 2000; 162: 1987-2001
  10. Rodriguez-Panadero F, Antony VB. Pleurodesis: State of the art. Eur Respir J 1997; 10: 1648-54
  11. Metintas M, Ucgun I, Elbek O, et al. Computed tomography features in malignant pleural mesothelioma and other commonly seen pleural disease. Eur J Radiol 2002; 41: 1-9
  12. Rodriguez-Panadero F. Effuions from malignancy. In: Light RW, Lee YC (eds). Textbook of Pleural Diseases. London: Arnold Press, 2003: 297-309
  13. Chahinian AP. Clinical presentation and natural history of mesothelioma: Pleural and pericardial. In: Pass HI, Vogelzang NJ, Carbone M (eds). Malignant Mesothelioma. New York: Springer Science + Business Media, 2005:380-90. 14. de Campos JR, Vargas FS, de Campos Werebe E, et al. Thoracoscopy talc poudrage: A 15-year experience. Chest 2001; 119: 801-6
  14. Metintas M, Metintas S, Ucgun I, et al. Prognostic factors in diffuse malignant pleural mesothelioma: Effects of pretreatment clinical and laboratory characteristics. Respir Med